The 2nd World Congress on Interventional Therapies for Type 2 Diabetes is endorsed by the following organizations.

Educational Partner: American Diabetes Association

ENDORSING SOCIETIES:

American Association of Clinical Endocrinologists
American Association of Endocrine Surgeons
American Gastroenterological Association
American Society for Metabolic and Bariatric Surgery

Asociacion De Cirugia Bariatrica Y Metabolica De Guatemala

Asia Pacific, Metabolic & Bariatric Surgery Society
Asociacion Latinoamericana De Cirujanos Endoscopistas
Association for the Study of Obesity

Belgian Endocrine Society
Diabetes UK
Endocrine Society
European Association for Endoscopic Surgery

European Association for the Study of Diabetes

Indian Association of Gastrointestinal Endo-Surgeons
International Atherosclerosis Society

International Federation for the Surgery of Obesity and Metabolic Disorders
Italian Society of Endocrinology
Japan Society for the Study of Obesity
National Obesity Forum

2nd World Congress on Interventional Therapies for Type 2 Diabetes • March 28-30, 2011 • New York, NY, USA • www.wcidt.org
The 2nd World Congress on Interventional Therapies for Type 2 Diabetes is Endorsed by the Following Organizations.

**ENDORSING SOCIETIES**

- Obesity & Metabolic Surgery Society of India
- The Obesity Society
- Obesity Surgery Society of Australia & New Zealand
- The Philippine Society for Metabolic and Bariatric Surgery
- Qatar Diabetes Association – Qatar Foundation
- Sociedad Argentina de Diabetes
- Sociedad Española de Diabetes
- Società Italiana dell’Obesità
- Società Italiana di Chirurgia dell’Obesità e delle malattie metaboliche
- Society for Endocrinology
- Society of American Gastrointestinal and Endoscopic Surgeons
- The Society for Surgery of the Alimentary Tract
- Swiss Society for the Study of Morbid Obesity and Metabolic Disorders

This program is supported in name only by the American Heart Association's Councils on Basic Cardiovascular Sciences, Clinical Cardiology, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, Kidney in CV Disease, and High Blood Pressure Research. http://www.heart.org/HEARTORG/
Specific themes of the World Congress include:

- Epidemiology and economic impact of diabetes
- Latest research findings on interventional therapies for type 2 diabetes
- Current recommendations/guidelines for surgical treatment of diabetes
- Impact of interventional therapies on cardiovascular risk in diabetic patients
- Role of integrated surgical and medical approaches for diabetes (multimodality therapies)
- Novel technologies and gastrointestinal devices for diabetes
- Cost effectiveness of surgery as a treatment for diabetes
- Conventional paradigms vs. novel ideas on the etiology of diabetes and obesity: debate by leading scientists in the field
- Mechanisms of surgical control of diabetes and gastrointestinal targets for drug development

Who Should Attend?

This Congress is designed for professionals in the fields of endocrinology, diabetes, bariatric/metabolic surgery, cardiology, epidemiology, gastroenterology, internal medicine, family medicine, pharmacology, nutrition, basic science, and public health, as well as allied health professionals, policy makers, and scientists from the pharmaceutical and medical device industries.

Register now at www.wcidt.org
Congress Program Committee

CONGRESS DIRECTOR
FRANCESCO RUBINO, MD
Weill Cornell Medical College
New York, NY, USA

PROGRAM COMMITTEE MEMBERS

DOMENICO ACCILI, MD
Columbia University Medical Center
New York, NY, USA

LOUIS ARONNE, MD
Weill Cornell Medical College
New York, NY, USA

RICARDO V. COHEN, MD
The Center for the Surgical Treatment of Obesity and Metabolic Disorders
Hospital Oswaldo Cruz
Sao Paulo, Brazil

JOHN DIXON, MBBS, PhD
Baker IDI Heart and Diabetes Institute
Melbourne, Australia

SAMUEL KLEIN, MD
Washington University School of Medicine
St. Louis, MO, USA

RUDOLPH L. LEIBEL, MD
Columbia University Medical Center
New York, NY, USA

CAREL W. LE ROUX, MRCP, PhD
Imperial College
London, UK

TIMOTHY E. MCGRAW, PhD
Weill Cornell Medical College
New York, NY, USA

JEFFREY I. MECHANICK, MD
American Association of Clinical Endocrinologists
New York, NY, USA

JESSE ROTH, MD
Albert Einstein College of Medicine
Manhasset, NY, USA

CLINICAL TRACK

Chair
HAROLD E. LEBOVITZ, MD
State University of New York,
Health Science Center
Brooklyn, NY, USA

Co-Chair
PHILIP SCHAUER, MD
Cleveland Clinic
Cleveland, OH, USA

RESEARCH TRACK

Chair
DAVID E. CUMMINGS, MD
Diabetes Endocrinology
Research Center
University of Washington
Seattle, WA, USA

Co-Chair
LEE M. KAPLAN, MD, PhD
Harvard Medical School
Boston, MA, USA

POLICY TRACK

Chair
PAUL ZIMMET, MD, PhD
Baker IDI Heart and Diabetes Institute
Melbourne, Australia

Co-Chair
DAVID FLUM, MD, MPH
University of Washington
Seattle, WA, USA

ADVISORY COMMITTEE MEMBERS

Linda Cann, MSEd (Alexandria, VA, USA), Ricardo V. Cohen, MD (Sao Paulo, Brazil), David E. Cummings, MD (Seattle, WA, USA), Antonio M. Gotto, JR., MD, DPhil (New York, NY, USA), Lee M. Kaplan, MD, PhD (Boston, MA, USA), M. Sue Kirkman, MD (Alexandria, VA, USA), Harold E. Lebovitz, MD (Brooklyn, NY, USA), Fabrizio Michelassi, MD (New York, NY, USA), Alfons Pomp, MD (New York, NY, USA), Philip Schauer, MD (Cleveland, OH, USA), Paul Zimet, MD, PhD (Melbourne, Australia).
Program Format

Plenary Sessions

There will be three Congress tracks: clinical, research, and policy. Each track has multiple sessions. The program of each Congress session includes state-of-the-art lectures providing a review of available data. The lectures will be followed by an interactive expert panel discussion as well as Q&A time with the audience. The panel debates are the signature feature of this congress and will provide an opportunity for interactive discussions.

Breakout Sessions (Tuesday evening, March 29th)

The Faculty and audience will divide into separate rooms for each of the three tracks. Faculty designates will lead with a prepared selection of evidence-based topics and potential conclusions that are designed to capture the consensus of session participants. Each of these breakout sessions will last for 2 hours.

Conclusive Plenary Session (Wednesday, March 30th)

A summary of the conclusions of the three breakout sessions will be presented by a Faculty representative in the final plenary session of the Congress. An interactive voting system will be used to verify which conclusions obtain the greatest enthusiasm and support from the participants. This process will ultimately generate an executive summary of the main Congress outcomes.

After the Congress

Shortly after the New York meeting, a dedicated Writing Committee will draft a consensus document detailing the outcomes of the Conclusive Plenary Session. Its aim and content is not to generate new clinical guidelines, but to highlight the most important messages from the World Congress. Inevitably, it will indicate areas of research that should receive priority and call to action appropriate policy changes. This will be submitted to a relevant medical journal for publication as a white paper.
Distinguished Faculty

DOMENICO ACCILI, MD
Columbia University Medical Center
New York, NY, USA

TED D. ADAMS, PhD, MPH
University of Utah School of Medicine
Health & Fitness Institute, LDS Hospital
Salt Lake City, UT, USA

K. GEORGE ALBERTI, MA, DPhil, BM BCh
Imperial College London
London, UK

HANAN AL KUWARI, PhD
Hamad Medical Corporation
Doha, Qatar

STEPHANIE A. AMIEL, MD
Kings College London
London, UK

CAROLINE M. APOVIAN, MD
Boston University School of Medicine
Boston, MA, USA

LOUIS ARONNE, MD
Weill Cornell Medical College
New York, NY, USA

NICOLA BASSO, MD
Università degli Studi di Roma "La Sapienza"
Rome, Italy

RICHARD N. BERGMAN, PhD
University of Southern California
Los Angeles, CA, USA

ZACHARY T. BLOOMGARDEN, MD
Mount Sinai School of Medicine
New York, NY, USA

STACY A. BRETHAUGER, MD
Cleveland Clinic
Cleveland, OH, USA

MICHAEL S. BROWN, MD
University of Texas Southwestern Medical Center
Dallas, TX, USA

HENRY BUCHWALD, MD, PhD
University of Minnesota Medical School
Minneapolis, MN, USA

PRADEEP CHOWBHEY, MS
Institute of Minimal Access, Metabolic & Bariatric Surgery
Max Healthcare
New Delhi, India

RICARDO V. COHEN, MD
The Center for the Surgical Treatment of Obesity and Metabolic Disorders
Hospital Oswaldo Cruz
Sao Paulo, Brazil

DAVID E. CUMMINGS, MD
Diabetes Endocrinology Research Center
University of Washington
Seattle, WA, USA

TAMARA DARSW, PhD
American Diabetes Association
Alexandria, VA, USA

ARA DARZI, MD
Imperial College London
London, UK

RALPH DEFRONZO, MD
School of Medicine, UT Health Science Center, San Antonio
San Antonio, TX, USA

STEFANO DEL PRATO, MD
University of Pisa
Pisa, Italy

AUREO DE PAULA, MD
Hospital de Especialidades
Goiania, Brazil

JOHN DIXON, MBBS, PhD
Baker IDI Heart and Diabetes Institute
Melbourne, Australia

ROBERT H. ECKEL, MD
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO, USA

ELE FERRANNINI, MD
University of Pisa
Pisa, Italy

DAVID FLUM, MD, MPH
University of Washington
Seattle, WA, USA

JOHN FUNDER, MD, PhD
Prince Henry's Institute
Clayton, VIC, Australia

MICHIEL GAGNER, MD, PhD
Herbert Wertheim College of Medicine
Florida International University
Miami, FL, USA

MANOEL GALVAO NETO, MD
Gastro Obeso Center
São Paulo, Brazil

ROBIN S. GOLAND, MD
Columbia University College of Physicians & Surgeons
New York, NY, USA

ALLISON B. GOLDFINE, MD
Joslin Diabetes Center
Boston, MA, USA

JOSEPH L. GOLDSTEIN, MD
University of Texas Southwestern Medical Center
Dallas, TX, USA

ANTONIO M. GOTTO, JR., MD, DPhil
Weill Cornell Medical College
New York, NY, USA

JAN WILLEM M. GREVE, MD
Atrium Medical Center Parkstad
Heerlen, The Netherlands

YUSUKE HADA, MD
Tokyo University School of Medicine
Tokyo, Japan

BJØRN M. HOFMANN, MSC, PhD
Center for Medical Ethics
University of Oslo and University College of Gjøvik
Oslo and Gjøvik, Norway

JENS JUUL HOLST, MD
Copenhagen University
Copenhagen, Denmark

LINONG JI, MD
Peking University People's Hospital
Beijing, China
Distinguished Faculty

SHASHANK R. JOSHI, MD, DM
Grant Medical College and Sir JJ
Group of Hospitals
Mumbai, India

STEVEN E. KAHN, MB, ChB
VA Puget Sound Health Care System
and University of Washington
Seattle, WA, USA

LEE M. KAPLAN, MD, PhD
Harvard Medical School
Boston, MA, USA

CATHERINE KEATING, MPH
Deakin University
Melbourne, Australia

M. SUE KIRKMAN, MD
American Diabetes Association
Alexandria, VA, USA

SAMUEL KLEIN, MD
Washington University School of Medicine
St. Louis, MO, USA

JUDITH KORNER, MD, PhD
Columbia University College of Physicians and Surgeons
New York, NY, USA

BLANDINE B. LAFERRERE, MD
New York Obesity Nutrition Research Center
Columbia University College of Physicians and Surgeons
New York, NY, USA

HAROLD E. LEOVITZ, MD
State University of New York, Health Science Center
Brooklyn, NY, USA

FRANK LEFEVRE, MD
Northwestern University Feinberg School of Medicine
BCBSA Technology Evaluation Center
Chicago, IL, USA

RUDOLPH L. LEIBEL, MD
Columbia University Medical Center
New York, NY, USA

CAREL W. LE ROUX, MRCP, PhD
Imperial College
London, UK

RUTH E. LEY, PhD
Cornell University
Ithaca, NY, USA

RUI LI, PhD
Centers for Disease Control and Prevention
Atlanta, GA, USA

TIMOTHY E. MCGRAW, PhD
Weill Cornell Medical College
New York, NY, USA

JEFFREY I. MECHANICK, MD
American Association of Clinical Endocrinologists
New York, NY, USA

GELTRUDE MINGRONE, MD, PhD
Università Cattolica del S. Cuore
Rome, Italy

F. XAVIER PI-SUNYER, MD
Columbia University College of Physicians and Surgeons
New York, NY, USA

ALFONS POMP, MD
Weill Cornell Medical College
New York, NY, USA

WALTER PORIES, MD
East Carolina University, Brody School of Medicine
Greenville, NC, USA

JESSE ROTH, MD
Albert Einstein College of Medicine,
Yeshiva University
Feinstein Institute for Medical Research
Manhasset, NY, USA

FRANCESCO RUBINO, MD
Weill Cornell Medical College
New York, NY, USA

MOH’D. FATHY SAoud, PhD
Qatar Foundation
Doha, Qatar

PHILIP SCHAUER, MD
Cleveland Clinic
Cleveland, OH, USA

GARY J. SCHWARTZ, PhD
Albert Einstein College of Medicine
Bronx, NY, USA

RANDY J. SEELEY, PhD
Metabolic Diseases Institute
University of Cincinnati
Cincinnati, OH, USA

HARVEY J. SUGERMAN, MD
Virginia Commonwealth University
Richmond, VA, USA

GERALD SHULMAN, MD, PhD
Howard Hughes Medical Institute
Yale School of Medicine
New Haven, CT, USA

LARS SJÖSTRÖM, MD, PhD
Institute of Internal Medicine
Sahlgrenska University Hospital
Göteborg, Sweden

MYRLENE STATEN, MD
NIDDK, National Institutes of Health
Bethesda, MD, USA

SEAN D. SULLIVAN, PhD
School of Pharmacy, University of Washington
Seattle, WA, USA

TESS VAN DER MERWE, MBChB, PhD
University of Pretoria
Pretoria, South Africa

BRUCE M. WOLFE, MD
Oregon Health & Science University
Portland, OR, USA

CAROL H. WYSHAM, MD
University of Washington School of Medicine
Seattle, WA, USA

JAMES YOUNG, MD
Cleveland Clinic
Cleveland, OH, USA

PAUL ZIMMET, MD, PhD
Baker IDI Heart and Diabetes Institute
Melbourne, Australia
## 2nd World Congress on Interventional Therapies for Type 2 Diabetes

### Scientific Program

**MONDAY, MARCH 28, 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 am</td>
<td><strong>Opening Ceremony</strong></td>
</tr>
<tr>
<td>8:20 am</td>
<td><strong>Introduction of the World Congress: Scope and Methods</strong></td>
</tr>
<tr>
<td></td>
<td>F. Rubino (New York, NY, USA)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CLINICAL TRACK SESSION I</strong></th>
<th>8:35 am - 10:50 am</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Outcomes of Conventional and Surgical Treatments for T2DM</strong></td>
<td></td>
</tr>
<tr>
<td>Chairs: W. Pories (Greenville, NC, USA) • H.E. Lebovitz (Brooklyn, NY, USA)</td>
<td></td>
</tr>
<tr>
<td>8:35 am - 8:55 am</td>
<td>Glycemic and metabolic control with current pharmacologic treatments</td>
</tr>
<tr>
<td></td>
<td>S. Del Prato (Pisa, Italy)</td>
</tr>
<tr>
<td>8:55 am - 9:15 am</td>
<td>Glycemic and metabolic outcomes with bariatric/metabolic surgery: overview</td>
</tr>
<tr>
<td></td>
<td>P. Schauer (Cleveland, OH, USA)</td>
</tr>
<tr>
<td>9:15 am - 9:30 am</td>
<td>Long-term prevention and remission of diabetes after bariatric surgery in the SOS study</td>
</tr>
<tr>
<td></td>
<td>L. Sjöström (Göteborg, Sweden)</td>
</tr>
<tr>
<td>9:30 am - 9:45 am</td>
<td>Safety profiles of pharmaceutical approaches</td>
</tr>
<tr>
<td></td>
<td>H.E. Lebovitz (Brooklyn, NY, USA)</td>
</tr>
<tr>
<td>9:45 am - 10:00 am</td>
<td>Safety profiles of surgical approaches: short and long term</td>
</tr>
<tr>
<td></td>
<td>B.M. Wolfe (Portland, OR, USA)</td>
</tr>
<tr>
<td>10:00 am - 10:50 am</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td></td>
<td>Panelists: S.A. Amiel (London, UK), Z.T. Bloomgarden (New York, NY, USA), J. Dixon (Melbourne, Australia), A. Pomp (New York, NY, USA), H. Buchwald (Minneapolis, MN, USA), A.B. Goldfine (Boston, MA, USA), K.G. Alberti (London, UK), J.I. Mechanick (New York, NY, USA), X. Pi-Sunyer (New York, NY, USA)</td>
</tr>
</tbody>
</table>

| **COFFEE BREAK** | |
| 10:50 am - 11:10 am |

<table>
<thead>
<tr>
<th><strong>POLICY TRACK SESSION I</strong></th>
<th>11:10 am - 12:30 pm</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>The International Diabetes Federation (IDF) Position Statement on Interventional Treatments of Type 2 Diabetes</strong></td>
<td></td>
</tr>
<tr>
<td>Chairs: J. Dixon (Melbourne, Australia) • K.G. Alberti (London, UK)</td>
<td></td>
</tr>
<tr>
<td>11:10 am - 11:20 am</td>
<td><strong>Existing guidelines for surgical treatment of obesity and diabetes (NIH, DSS, ADA)</strong></td>
</tr>
<tr>
<td></td>
<td>L.M. Kaplan (Boston, MA, USA)</td>
</tr>
<tr>
<td>11:20 am - 11:40 am</td>
<td><strong>The IDF position statement on interventional therapies for type 2 diabetes</strong></td>
</tr>
<tr>
<td></td>
<td>P. Zimmet (Melbourne, Australia)</td>
</tr>
<tr>
<td>11:40 am - 12:30 pm</td>
<td><strong>Panel Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>Panelists: C. Wysham (ADA) (Seattle, WA, USA), J.I. Mechanick (AACE) (New York, NY, USA), S.A. Amiel (Diabetes UK) (London, UK), X. Pi-Sunyer (NHLBI) (New York, NY, USA), A.M. Gotto (New York, NY, USA), F. Rubino (New York, NY, USA), R.H. Eckel (Aurora, CO, USA)</td>
</tr>
</tbody>
</table>

| **LUNCH BREAK** | |
| 12:30 pm - 1:30 pm |
### CLINICAL TRACK SESSION II | 1:30 pm - 3:00 pm

**CV Risk Reduction and Survival in Patients with Diabetes: Medical versus Surgical Therapy**  
_Chairs: A.M. Goto (New York, NY, USA) • K.G. Alberti (London, UK)_

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:30 pm - 1:50 pm</td>
<td>CV risk, CVD and diabetes-related mortality: impact of pharmacologic approaches</td>
<td>R.H. Eckel (Aurora, CO, USA)</td>
</tr>
<tr>
<td>1:50 pm - 2:05 pm</td>
<td>Long-term (20 years) impact of bariatric surgery on CV risk and CVD: an update from the SOS study</td>
<td>L. Sjöström (Göteborg, Sweden)</td>
</tr>
<tr>
<td>2:05 pm - 2:15 pm</td>
<td>The impact of bariatric/metabolic surgery on CV risk and long-term survival</td>
<td>T.D. Adams (Salt Lake City, UT, USA)</td>
</tr>
<tr>
<td>2:15 pm - 3:00 pm</td>
<td>Panel Discussion</td>
<td>R. DeFronzo (San Antonio, TX, USA), E. Ferrannini (Pisa, Italy), S.R. Joshi (Mumbai, India), S.E. Kahn (Seattle, WA, USA), J. Young (Cleveland, OH, USA), H.J. Sugerman (Richmond, VA, USA), W. Pories (Greenville, NC, USA)</td>
</tr>
</tbody>
</table>

3:00 pm - 3:20 pm | COFFEE BREAK |

### CLINICAL TRACK SESSION III | 3:20 pm - 5:45 pm

**Diabetes Surgery: Indications, Choice of Procedure & Peri-Operative Management**  
_Chairs: R.S. Goland (New York, NY, USA) • L. Aronne (New York, NY, USA)_

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:20 pm - 3:35 pm</td>
<td>Predicting factors of diabetes control/reasonable criteria for surgical indication</td>
<td>J. Kornr (New York, NY, USA)</td>
</tr>
<tr>
<td>3:35 pm - 3:50 pm</td>
<td>Preoperative management of diabetic patients</td>
<td>C.M. Apovian (Boston, MA, USA)</td>
</tr>
<tr>
<td>3:50 pm - 4:05 pm</td>
<td>Which surgical procedure is best? Summary of available evidence from comparative clinical studies in high and low BMI patients</td>
<td>H.J. Sugerman (Richmond, VA, USA)</td>
</tr>
<tr>
<td>4:05 pm - 4:40 pm</td>
<td>Panel Discussion</td>
<td>R. DeFronzo (San Antonio, TX, USA), E. Ferrannini (Pisa, Italy), S.R. Joshi (Mumbai, India), S.E. Kahn (Seattle, WA, USA), J. Young (Cleveland, OH, USA), H.J. Sugerman (Richmond, VA, USA), W. Pories (Greenville, NC, USA)</td>
</tr>
<tr>
<td>4:40 pm - 4:55 pm</td>
<td>Postoperative management of obese and diabetic patients; the role of integrated/multimodality therapies</td>
<td>L. Aronne (New York, NY, USA)</td>
</tr>
<tr>
<td>4:55 pm - 5:15 pm</td>
<td>A rational and physiologic approach to the management of diabetes after surgery</td>
<td>R. DeFronzo (San Antonio, TX, USA)</td>
</tr>
<tr>
<td>5:15 pm - 5:45 pm</td>
<td>Panel Discussion</td>
<td>C. Wysham (Seattle, WA, USA), S.E. Kahn (Seattle, WA, USA), R.N. Bergman (Los Angeles, CA, USA), L. Ji (Beijing, China), S. Del Prato (Pisa, Italy)</td>
</tr>
</tbody>
</table>

5:45 pm - 6:45 pm | POSTER SESSION |

8:00 pm | WELCOME RECEPTION |
# Scientific Program

**TUESDAY, MARCH 29, 2011**

## RESEARCH TRACK SESSION I  7:30 am - 9:40 am

### Mechanisms of Action of Surgery

Chair: L.M. Kaplan (Boston, MA, USA) • S.E. Kahn (Seattle, WA, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 am - 7:45 am</td>
<td>Mechanisms of Weight Loss: beyond restriction and malabsorption</td>
<td>R.J. Seeley (Cincinnati, OH, USA)</td>
</tr>
<tr>
<td>7:45 am - 8:00 am</td>
<td>Effect of GI surgery on insulin secretion/sensitivity</td>
<td>S. Klein (St. Louis, MO, USA)</td>
</tr>
<tr>
<td>8:00 am - 8:15 am</td>
<td>Effects of GI surgery on food choices and energy expenditure</td>
<td>C.W. Le Roux (London, UK)</td>
</tr>
<tr>
<td>8:15 am - 8:30 am</td>
<td>Effects of GI surgery on glucose homeostasis</td>
<td>J.J. Holst (København, Denmark)</td>
</tr>
<tr>
<td>8:30 am - 9:00 am</td>
<td>Debate: Diabetes control by GI surgery is explained by weight-independent mechanisms</td>
<td>Yes: D.E. Cummings (Seattle, WA, USA)</td>
</tr>
<tr>
<td>8:30 am - 8:45 am</td>
<td></td>
<td>No: E. Ferrannini (Pisa, Italy)</td>
</tr>
<tr>
<td>9:00 am - 9:40 am</td>
<td>Panel Discussion: Weight independent mechanisms of diabetes control: weighing the evidence</td>
<td>Panelists: J. Korner (New York, NY, USA), G. Mingrone (Rome, Italy), R.N. Bergman (Los Angeles, CA, USA), R. DeFronzo (San Antonio, TX, USA), B.B. Laferriere (New York, NY, USA), G.J. Schwartz (New York, NY, USA)</td>
</tr>
</tbody>
</table>

## RESEARCH TRACK SESSION II  9:40 am - 11:10 am

### Novel Experimental Approaches for Diabetes/Obesity

Chair: H. Buchwald (Minneapolis, MN, USA) • S. Klein (St. Louis, MO, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:40 am - 9:55 am</td>
<td>Novel GI surgical procedures (DJB and Ileal Interposition: alone and with associated sleeve gastrectomy)</td>
<td>R.V. Cohen (Sao Paulo, Brazil)</td>
</tr>
<tr>
<td>9:55 am - 10:10 am</td>
<td>Endoluminal procedures for obesity/diabetes</td>
<td>S.A. Brethauer (Cleveland, OH, USA)</td>
</tr>
<tr>
<td>10:10 am - 10:25 am</td>
<td>Endoluminal devices for obesity/diabetes</td>
<td>L.M. Kaplan (Boston, MA, USA)</td>
</tr>
<tr>
<td>10:25 am - 10:40 am</td>
<td>Pacing/GI electric stimulation for diabetes</td>
<td>H.E. Lebovitz (Brooklyn, NY, USA)</td>
</tr>
<tr>
<td>10:40 am - 11:10 am</td>
<td>Panel Discussion</td>
<td>Panelists: J. Greve, (Heerlen, Netherlands), M. Galvao Neto (Sao Paulo, Brazil), A. De Paula (Goiania, Brazil), W. Poires (Greenville, NC, USA), J. Funder (Clayton, Australia), S.R. Joshi ((Mumbai, India)</td>
</tr>
<tr>
<td>11:10 am - 11:30 am</td>
<td>COFFEE BREAK</td>
<td></td>
</tr>
</tbody>
</table>
TUESDAY, MARCH 29, 2011  (continued)

RESEARCH TRACK SESSION III  | 11:30 am - 1:00 pm

**Defining Priorities for Clinical Research in Metabolic/Diabetes Surgery**

Chairs: A.B. Goldfine (Boston, MA, USA) • J. Roth (Manhasset, NY, USA)

11:30 am - 11:45 am  
Clinical trials in diabetes surgery: overview of ongoing trials; challenges for study design, practical issues in surgical trials  
A.B. Goldfine (Boston, MA, USA)

11:45 am - 12:00 pm  
Clinical trials in diabetes surgery: ethical aspects  
B.M. Hofmann (Oslo, Norway)

12:00 pm - 12:15 pm  
Advantages and disadvantages of each design, multisite vs consortium model for large clinical trials  
F. Rubino (New York, NY, USA)

12:15 pm - 1:00 pm  
Panel Discussion: Priorities for clinical research in diabetes surgery; costs/funding, ethical aspects  
Panelists: P. Schauer (Cleveland, OH, USA), R. DeFronzo (San Antonio, TX, USA), J. Korner (New York, NY, USA), L. Sjöström (Göteborg, Sweden), M. Stating (NIH/NIDDK) (Bethesda, MD, USA), F. Saoud (Qatar Foundation) (Doha, Qatar), T. Darsaw (ADA) (Alexandria, VA, USA)

1:00 pm - 2:00 pm  
LUNCH BREAK

POLICY TRACK SESSION II  | 2:00 pm - 3:00 pm

**Global Burden of Diabetes and Resource Availability for Interventional Approaches**

Chairs: P. Zimmet (Melbourne, Australia) • P. Chowbey (New Delhi, India)

2:00 pm - 2:15 pm  
The global epidemiology of diabetes  
P. Zimmet (Melbourne, Australia)

2:15 pm - 2:30 pm  
The global costs of diabetes  
R. Li (CDC) (Atlanta, GA, USA)

2:30 pm - 3:00 pm  
Panel Discussion: Specific regional challenges for diabetes prevention and treatment  
Panelists: L. Ji (Beijing, China), J. Funder (Clayton, Australia), T. Van Der Merwe (Pretoria, South Africa), A. Darzi (London, UK), H. Al Kuwari (Doha, Qatar)

POLICY TRACK SESSION III  | 3:00 pm - 4:30 pm

**Cost Effectiveness of Diabetes Surgery: Implications for Public and Private Health Insurance**

Chairs: A. Darzi (London, UK) • D. Flum (Seattle, WA, USA)

3:00 pm - 3:15 pm  
Review of what we know about cost-effectiveness of bariatric surgery with special regard to patients with diabetes  
C. Keating (Burwood, Australia)

3:15 pm - 3:30 pm  
How governments consider evidence on cost-effectiveness  
S.D. Sullivan (Seattle, WA, USA)

3:30 pm - 3:45 pm  
How payers consider the evidence of cost and effectiveness  
F. Lefevre (Chicago, IL, USA)

3:45 pm - 4:30 pm  
Panel Discussion: Simply cost-effective? Reconciling cost-evaluations related to diabetes interventions  
Panelists: R. Li (CDC) (Atlanta, GA, USA), C. Keating (Burwood, Australia), S.D. Sullivan (Seattle, WA, USA), F. Lefevre (Chicago, IL, USA)
Scientific Program

TUESDAY, MARCH 29, 2011  (continued)

4:30 pm - 4:50 pm  COFFEE BREAK

BREAKOUT SESSIONS AND WORKSHOPS  4:50 pm - 6:50 pm

4:50 pm - 6:50 pm  Break-out Sessions for Review of Evidence, Interacting Discussion and Preparation of Executive Summary

Session A: CLINICAL TRACK
Defining appropriate surgical candidates and good clinical practice for perioperative management and post-operative follow-up
Chairs: H.E. Lebovitz (Brooklyn, NY, USA) • P. Schauer (Cleveland, OH, USA)
Program: To be announced

Session B: RESEARCH TRACK
Defining clinical research priorities
Chairs: D.E. Cummings (Seattle, WA, USA) • L.M. Kaplan (Boston, MA, USA)
Program: To be announced

Session C: POLICY TRACK
Chairs: P. Zimmet (Melbourne, Australia) • D. Flum (Seattle, WA, USA)

Workshop A: “Creating a pathway to reconcile professional guidelines”
4:50 pm - 5:00 pm  Summary lecture
J.B. Dixon (Melbourne, Australia)

5:00 pm - 5:40 pm  Panel Discussion/Round Table with official representatives of the following organizations: NHLBI Obesity Guidelines (X. Pi-Sunyer), ADA (C. Wysham), AACE (J.I. Mechanick), ASMBS (B. Wolfe), TOS (C.M. Apowian), SBCBM (R.V. Cohen), SICOB (N. Basso)

5:40 pm - 5:50 pm  Interactive Polls

Workshop B: “Payer perspectives: creating a pathway for policymakers and payers to reconcile approaches”
5:50 pm - 6:00 pm  Summary lecture:
D. Flum (Seattle, WA, USA)

6:00 pm - 6:40 pm  Panel Discussion/Round Table
F. Lefevre, (Chicago, IL, USA), S.D. Sullivan, (Seattle, WA, USA), A. Darzi, (London, UK), J. Funder, (Clayton, Australia), Y. Hada, (Tokyo, Japan), L. Ji, (Beijing, China), C. Keating, (Buswood, Australia), T. Van Der Merwe, (Pretoria, South Africa), H. Al Kuwari (Doha, Qatar)

6:40 pm - 6:50 pm  Interactive Polls
2ND WORLD CONGRESS ON INTERVENTIONAL THERAPIES FOR TYPE 2 DIABETES

Scientific Program

WEDNESDAY, MARCH 30, 2011

KEYNOTE LECTURE | 8:00 am - 9:00 am

8:00 am - 9:00 am  Surviving Starvation: Essential Role of the Ghrelin-Growth Hormone Axis
M.S. Brown (Dallas, TX, USA)
J.L. Goldstein (Dallas, TX, USA)

The Nobel Prize in Physiology or Medicine 1985 was awarded jointly to Michael S. Brown and Joseph L. Goldstein “for their discoveries concerning the regulation of cholesterol metabolism”.

RESEARCH TRACK SESSION IV | 9:00 am - 10:40 am

The role of the gut in the physiology and pathophysiology of obesity and diabetes
Chairs: T.E. McGraw (New York, NY, USA) • D. Accili (New York, NY, USA)

9:00 am - 9:20 am  Conventional paradigm of the pathophysiology of obesity
R.L. Leibel (New York, NY, USA)

9:20 am - 9:40 am  Conventional paradigm of the pathophysiology of diabetes
R.N. Bergman (Los Angeles, CA, USA)

9:40 am - 10:00 am  The physiologic role of the gut in energy and glucose homeostasis
J.J. Holst (Copenhagen, Denmark)

10:00 am - 10:20 am  Impaired GI physiology in individuals with diabetes/obesity
D.E. Cummings (Seattle, WA, USA)

10:20 am - 10:40 am  The role of intestinal microbiota in insulin resistance, obesity/diabetes
R.E. Ley (Ithaca, NY, USA)

10:40 am - 11:00 am  COFFEE BREAK

PANEL DISCUSSION | 11:00 am - 12:00 pm

The GI tract: could it be the missing link between obesity and diabetes?

11:00 am - 11:05 am  Introduction
F. Rubino (New York, NY, USA)

11:05 am - 12:00 pm  Panel Discussion
M.S. Brown (Dallas, TX, USA), J.L. Goldstein (Dallas, TX, USA), G. Shulman (New Haven, CT, USA), S. Klein (Cincinnati, OH, USA), R. DeFronzo (San Antonio, TX, USA), S.E. Kahn (Seattle, WA, USA), J. Roth (Manhasset, NY, USA), L.M. Kaplan (Boston, MA, USA)
## EXECUTIVE SUMMARIES/TAKE HOME MESSAGE  12:00 pm - 1:15 pm

**Presentation of executive summaries and conclusions**  
Chairs: M. Sue Kirkman (Alexandria, VA, USA) • W. Pories (Greenville, NC, USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 pm - 12:12 pm</td>
<td><strong>Clinical Practice</strong></td>
<td>H.E. Lebovitz (Brooklyn, NY, USA)</td>
<td></td>
</tr>
<tr>
<td>12:12 pm - 12:24 pm</td>
<td><strong>Priorities for Clinical Research</strong></td>
<td>D.E. Cummings (Seattle, WA, USA)</td>
<td></td>
</tr>
<tr>
<td>12:24 pm - 12:36 pm</td>
<td><strong>Reconciling Guidelines</strong></td>
<td>P. Zimmet (Melbourne, Australia)</td>
<td></td>
</tr>
<tr>
<td>12:36 pm - 12:48 pm</td>
<td><strong>Public Health Policies</strong></td>
<td>D. Flum (Seattle, WA, USA)</td>
<td></td>
</tr>
<tr>
<td>12:48 pm - 1:00 pm</td>
<td><strong>The evolving paradigm of diabetes pathogenesis</strong></td>
<td>J. Roth (Manhasset, NY, USA)</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 pm - 1:15 pm</td>
<td>INTERACTIVE OPINION POLLS</td>
</tr>
<tr>
<td>1:15 pm - 1:20 pm</td>
<td>CLOSING REMARKS</td>
</tr>
</tbody>
</table>
Congress Registration is now open! Register online at www.wcidt.org

The Congress registration fee includes: abstract book/final program and admission to all scientific sessions, exhibits, poster sessions, breakfasts, and coffee breaks. Registration rates for the 2nd World Congress on Interventional Therapies for Type 2 Diabetes are as follows. All registration fees are in US dollars.

Register by March 4th to save!

<table>
<thead>
<tr>
<th>Registration fees</th>
<th>By Mar 4, 2011</th>
<th>After Mar 4, 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians and Scientists</td>
<td>$590</td>
<td>$680</td>
</tr>
<tr>
<td>Members of Endorsing/Sponsoring Societies*</td>
<td>$490</td>
<td>$580</td>
</tr>
<tr>
<td>Medical Students/Residents*</td>
<td>$300</td>
<td>$350</td>
</tr>
<tr>
<td>Allied Health Professionals*</td>
<td>$360</td>
<td>$420</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>$85</td>
<td>$125</td>
</tr>
</tbody>
</table>

* Must provide proof of status to receive reduced rate.

The 2nd World Congress on Interventional Therapies for Type 2 Diabetes will take place at:

Hilton New York
1335 Avenue of the Americas
New York, New York, USA 10019
Tel: 1-212-586-7000

For additional information about the Hilton New York, visit http://wcidt.org/hotel-travel-information/

Make Your Reservation

Make your hotel reservation for the Congress online at www.wcidt.org

The Congress has negotiated special reduced rates for Congress attendees.

Rates: $219.00 per night Single/Double*

The Congress room rate is valid through Sunday, February 20, 2011 or until rooms are sold out.

For group reservations of 10 or more room nights, please contact the Congress Office at wcidt@gomeeting.com or by phone at +1.410.571.0590.

* Rate does not include New York city, state and occupancy tax of approximately 19.8% (total cost per night: $262.47). Please note that the Congress room block is limited and may fill before the deadline. Attendees are encouraged to book their hotel room early to avoid disappointment.
2nd World Congress on Interventional Therapies for Type 2 Diabetes
ATTENDEE ADVANCE REGISTRATION FORM (Page 1 of 2)
March 28-30, 2011 – Hilton New York, New York, NY USA

Online registration is available at: www.regonline.com/WCDIT

Return this form to address below or fax to +1 303 530 2691.

SECTION 1: ATTENDEE INFORMATION

First Name, Middle Name, Last Name____________________________________________________________________________

First Name on Badge (if different from above)______________________________________________________________________

Job Title______________________________________________________________

Company/Organization/Institution________________________________________________________________________________

Mailing Address________________________________________________________

City_______________________________________State/Province____________________Zip/Postal Code____________________

Country____________________________________Phone___________________________Fax ____________________________

Email Address_______________________________________________________________________________________________

Degree: □ MD □ MD/PhD □ MSc □ PhD □ DO □ Other, please specify____________________________

1) Specialty: Please indicate primary and secondary specialty, using a “1” and “2” in the fields below.

□ Endocrinology □ Nutrition
□ Diabetology □ Pharmacology
□ Metabolic/Bariatric Surgery □ Basic Science
□ Cardiology □ Public Health
□ Epidemiology □ Allied Health
□ Gastroenterology □ Policy
□ Internal Medicine □ Pharmaceutical/Medical Device Industry
□ Family Medicine □ Other, please specify____________________________

2) How did you hear about this event?

□ Email Mail □ Word of Mouth
□ Mail/Postcard □ Conference Website
□ Advertisement at another conference □ Other____________________________

3) If you are a student, Post Doc, Resident or Intern, please enter your information below completely:

Director’s Name___________________________________   Director’s Facility__________________________

Program Director’s Email________________________________________

4) Special Needs

A) Please indicate any serious dietary allergies below (if none, leave blank). We will make every effort to incorporate a range of
dietary preferences into coffee breaks and reception functions, but please note that due to the large number of attendees,
individual preferences cannot be accommodated.

________________________________________________________

B) I require accommodations for my:

□ Wheelchair or other mobility impairment
□ Hearing Impairment
□ Other, please specify: ________________________________
SECTION 2: REGISTRATION FEES

<table>
<thead>
<tr>
<th>Category</th>
<th>11-Jan-11 to 4-Mar-11</th>
<th>After 4-Mar-11</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinicians and Scientists</td>
<td>$590</td>
<td>$680</td>
<td>$_____</td>
</tr>
<tr>
<td>Members of Endorsing/Sponsoring Societies*</td>
<td>$490</td>
<td>$580</td>
<td>$_____</td>
</tr>
<tr>
<td>Medical Students/Residents/Fellows*</td>
<td>$300</td>
<td>$350</td>
<td>$_____</td>
</tr>
<tr>
<td>Allied Health Professionals*</td>
<td>$360</td>
<td>$420</td>
<td>$_____</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>$85</td>
<td>$125</td>
<td>$_____</td>
</tr>
</tbody>
</table>

*If you have registered as an Endorsing/Sponsoring Member Societies or Medical Student/Resident, proof of status must accompany this registration form to receive the special rate. Please see notes below for each registration category.

1. Members of scientific societies that have endorsed and/or sponsored the Congress are eligible for a registration discount of $100 off the regular rate. Multiple memberships cannot be combined to increase the discount. To view a list of these organizations, please visit http://wcidt.org/endorsing-societies/. Proof of membership includes a letter from the society or a membership ID card. Please note that the Endorsing Society Membership discount only applies to physicians and scientists, who have a current membership. The $100 discount is already included in the Endorsing Society Member rate.

2. Medical Students/Residents: Proof of student status includes a letter from your department head or a copy of your student ID.

3. Allied Health Professionals are employed in the healthcare field, such as nurses, dieticians, nutritionists, etc. (not MDs, PhDs, MDs/PhDs or DOs). Proof of status includes a copy of your license, business card, or other proof of your position.

Payment Information
(Payment must accompany registration form in order to be processed.)

- Bank Check payable in US funds to “Giovanni Lorenzini Medical Foundation--WCIDT” (see address below to mail payment)
- VISA  MasterCard  American Express  Discover

<table>
<thead>
<tr>
<th>Card Number</th>
<th>Card ID Code</th>
<th>Expiration Date</th>
</tr>
</thead>
</table>

Billing Address (if different from above)

Cancellation/Refund Policy:
Written requests for Cancellations must be submitted by 5:00 PM Eastern Time (GMT -4) February 28, 2011 to be considered. There will be a 30% processing fee for all refunds. Refunds will not be processed until after the meeting. Refund requests after 5:00 PM Eastern time (GMT -4) February 28, 2011 will not be honored; however, those registrants will receive the scientific matter after the meeting. Substitutions after March 18, 2011 will be charged a $30.00 processing fee.

Send Cancellation/Refund Requests by:
Fax: +1 303 530 2691
Email: Gigi Andrew, gandrew@executivevents.com
Mail: WCIDT Registration Center
c/o Executive Events
4665 Nautilus Court, Suite 502
Boulder, CO 80301 USA

For more information regarding the Congress and accommodations, please see the WCIDT website, www.wcidt.org
Questions regarding registration, contact Gigi Andrew, gandrew@executivevents.com or call +1 303 530 0205 ext. 17
Question regarding the WCIDT Congress, contact wcidt@gomeeting.com or call +1 410 517 0590

Date________________________Signature ___________________________
Visionary Level Supporter

Qatar Foundation

Unlocking human potential.

Corporate Sponsors

Platinum Level

Ethicon Endo-Surgery

Gold Level

Allergan, Covidien

Silver Level

Medtronic

Bronze Level

Olympus, Karl Storz, sanofi aventis, Gore

We would also like to thank

MetaCure